Authors' reply to correspondence to "Mortality-related risk factors of inpatients with diabetes and COVID-19: A multicenter retrospective study in Belgium. Ann Endocrinol (Paris). 2023 Aug 31:S0003-4266(23)00685-6. doi:10.1016/j.ando.2023.08.002".
Authors’ reply: The correspondence raised important concerns regarding the optimization of antidiabetic therapy to improve COVID-19 outcomes for people with type-2 diabetes (T2D). In particular, the authors pointed out the additional benefits of glucagon-like peptide 1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) beyond glucose control. Recent guidelines for the management of T2D indeed emphasize the use of drugs that promote weight-loss and provide cardiorenal protection: GLP-1 RA and SGLT2i, in association with metformin or not [.].
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2023 |
Verlag/Hrsg.: |
Elsevier
|
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27377568 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/2078.1/281453 |